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 Abstract 
Objective: Type 2 Diabetes mellitus is a metabolic disorder characterized by chronic 
hyperglycemia and with a major feature of insulin resistance. Genetic association studies have 
suggested that ENPP1 might play a potential role in susceptibility to type 2 diabetes and obesity. 
Our study aimed to examine the association between ENPP1 and type 2 diabetes and obesity. 
Design: Association study between two SNPs, rs1044498 (K121Q) and rs7754561 of ENPP1 and 
diabetes and obesity in the Chinese Han population. 
Subjects: 1912 unrelated patients (785 male and 1127 female with a mean age 63.8 ± 9 years), 236 
IFG/IGT subjects (83 male and 153 female with a mean age 64 ± 9 years) and 2041 controls (635 
male and 1406 female with a mean age 58 ± 9 years).  
Measurements: Subjects were genotyped for two SNPs using TaqMan technology on an ABI7900 
system and tested by regression analysis. 
Results: By logistic regression analysis, rs1044498 (K121Q) and rs7754561 showed no statistical 
association with type 2 diabetes, obesity under additive, dominant and recessive models either 
before or after adjusting for sex and age. Haplotype analysis found a marginal association of 
haplotype C-G (p=0.05) which was reported in the previous study. 
Conclusion: Our investigation did not replicated the positive association found previously and 
suggested that the polymorphisms of ENPP1 might not play a major role in the susceptibility to 
type 2 diabetes or obesity in the Chinese Han population. 
 
Keywords: Type 2 diabetes, obesity, Chinese, single nucleotide polymorphism, ENPP1 
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 Introduction 
Diabetes mellitus is a metabolic disorder characterized by chronic hyperglycemia with 
disturbances of carbohydrate, fat and protein metabolism. WHO estimates that more than 180 
million people worldwide have diabetes and the number is likely to double by 2030. Meanwhile, 
the problem is considered to be much worse and more widespread in the developing countries, like 
China. 90% of diabetic cases are type 2 diabetes characterized by hyperglycemia due to a defect in 
insulin secretion usually with a contribution from insulin resistance. The role of genetic factors in 
the illness has been consistently supported by population, family and twin studies. The offspring 
of a diabetic parent has a 40% lifetime chance of developing diabetes in contrast to a population 
risk of 7%, and if both parents are affected, the risk rises to 70%(1). Twin studies have reported 
concordance rates of 0.20 to 0.91 in monozygotic twins and 0.10 to 0.43 in dizygotic twins(2). 
Genetic and genome-wide association studies in recent decades have identified many different 
candidate genes which are related to the susceptibility in a variety of populations(3, 4). 
The ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) gene, also known as plasma 
cell membrane glycoprotein 1 (PC-1) localizes on chromosome 6q23.2, a region which has been 
reported as being linked to obesity(5, 6), serum insulin levels(5) and type 2 diabetes(7) in different 
populations. ENPP1 encodes for a type II transmembrane glycoprotein which inhibits insulin 
receptor (IR) tyrosine kinase activity(8) and subsequent insulin signaling probably by direct 
interaction with α subunit of IR(9). The ENPP1 gene is up-regulated in peripheral insulin target 
tissues, such as fibroblasts, muscle and adipose tissue, in insulin resistance subjects with or 
without type 2 diabetes(10-12). The overexpression of ENPP1 increases insulin resistance in 
mammals(13). The presence of insulin resistance is the earliest detectable defect in pre-diabetic 
individuals and a major feature of type 2 diabetes(14). ENPP1 is considered as a candidate gene 
for the etiological and pharmacological study of type 2 diabetes. 
A number of studies investigating the effects of ENPP1 on insulin resistance and the pathogenesis 
of type 2 diabetes, obesity and other metabolic syndromes have focused on the association with 
genetic variants. Pizzuti and his colleagues first reported strong association between a 
nonsynonymous single nucleotide polymorphism (SNP) K121Q (rs1044498) on exon4 of ENPP1 
and insulin resistance(15). Subsequent cellular transfection experiments showed that the Q allele 
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 was several times more effective than the K allele in reducing insulin stimulation of IR 
autophosphorylation, insulin receptor substrate-1 phosphorylation, phosphatidylinositol 3-kinase 
activity, glycogen synthesis, and cell proliferation(16). During the last decade, genetic association 
studies have found positive association between K121Q and type 2 diabetes in the Caucasian 
population(17), in the South Asians living in the US and India(17), in African-Americans(18), and 
in the Dominican population(19). The Q allele has also been observed to increase the risk of 
myocardial infarction(20) and obesity in the Caucasian population(21). Meyre et al. found positive 
association between a three-allele risk haplotype (K121Q (rs1044498), IVS20delT-11 (rs1799774) 
and A-->G+1044TGA (rs7754561); QdelTG) and childhood obesity, morbid or moderate obesity 
in adults and type 2 diabetes(22). Conversely, negative results were also reported between K121Q 
and type 2 diabetes in the Chinese, Japanese and Caucasian populations(23-26). Recently, Meyre 
and his colleagues found no association of the QdelTG risk haplotype with adult obesity and type 
2 diabetes in the French population(27). In addition, recent genome-wide association studies have 
revealed a series of susceptibility SNPs of type 2 diabetes-related genes, which are mostly related 
to insulin secretion rather than insulin resistance(28) in large-scale samples and gene pools, but, 
with one exception(29), no evidence of association between ENPP1 and type 2 diabetes have been 
reported(3, 4). Our own study in which we examined two representative SNPs in sequence, 
rs1044498 (K121Q) and rs7754561, in a Chinese case-control population used the largest sample 
investigated in China so far, with the aim of providing enhanced detection power and investigating 
possible association between polymorphisms of ENPP1 and type 2 diabetes and obesity in the 
Chinese Han population. 
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 Methods 
Subjects and DNA preparation. For the case–control investigation, 1912 unrelated type 2 
diabetes patients and 236 IFG/IGT subjects were recruited from Shanghai, China. The patients 
consisted of 785 male and 1127 female with a mean age 63.8 ± 9 years (HbA1c, 7.4 ± 1.6%; 
fasting plasma glucose, 7.9 ± 2.9 mmol/l; BMI, 25.2 ± 3.4 kg/m2; waist/hip, 0.89 ± 0.06 ). The 
IFG/IGT subjects were made up of 83 male and 153 female with a mean age 64 ± 9 years ( HbA1c, 
6.2 ± 0.5%; fasting plasma glucose, 5.6 ± 0.68 mmol/l; BMI, 24.9 ± 3.2 kg/m2; waist/hip, 0.88 ± 
0.06). All patients and IFG/IGT were defined according to the World Health Organization criteria. 
Control subjects were enrolled from the same geographic region with fasting plasma glucose 
concentration < 6.1 mmol/l and consisted of 635 male and 1406 female with a mean age 58 ± 9 
years (HbA1c, 5.8 ± 0.6%; fasting plasma glucose, 4.9 ± 0.7 mmol/l; BMI, 24.6 ± 3.2 kg/m2; 
waist/hip, 0.86 ± 0.06). All values are expressed as mean ± SD as shown in Table 1. 
High-molecular-weight genomic DNA was prepared from venous blood using the QuickGene 
610L Automatic DNA/RNA Extraction System (Fijifilm, Tokyo, Japan).  
Genotyping. In order to insure that the minor allele frequencies (MAF) of the two polymorphisms 
were not too low in the Chinese Han population to distinguish between cases and controls, we 
checked the dbSNP database (http://www.ncbi.nlm.nih.gov/SNP/) and the hapmap human SNP 
database (http://www.hapmap.org/). The MAF of rs1044498 and rs7754561 are 0.111 and 0.311 
respectively in the Chinese Han population. 
Two SNPs (rs1044498 and rs7754561) were genotyped using TaqMan technology on an ABI7900 
system (Applied Biosystems, Foster City, California). All probes and primers were designed by 
the Assay-by-Design or Assay-on-Demand service of Applied Biosystems. The standard 5μL 
polymerase chain reaction (PCR) procedures were performed using TaqMan Universal PCR 
Master Mix reagent kits under the provided guidelines. Genotype data were obtained from more 
than 97% of the DNA samples and the duplicate quality control samples (32 samples) were 
included and genotyped with 100% concordance.  
Statistical analysis. The association of SNPs with type 2 diabetes was assessed by logistic 
regression. All analysis procedures were adjusted for sex, age and BMI. For the additive model, 
homozygotes (1/1), heterozygotes (1/0) for the risk allele and homozygotes for the non-risk allele 
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 (0/0) were encoded to an ordered categorical variable for genotypes (2, 1, and 0). The dominant 
model was defined as 1/1 + 1/0 versus 0/0 and the recessive model as 1/1 versus 1/0 + 0/0. 
Hardy-Weinberg equilibrium testing, allele, genotype and haplotype frequencies analysis were 
carried out online on a robust and user-friendly software platform (http://analysis.bio-x.cn/)(30) 
developed by our lab. It was used to estimate LD measured with standardized D’ and to compare 
the discrepancies of allele, genotype and haplotype frequencies on single loci between cases and 
controls using a Monte Carlo simulation strategy(31), the normal chi-square test and the odds ratio 
test. The same association study was repeated for obesity in the patients and controls. Obesity and 
non-obesity were defined as BMI≥28 kg/m2 and BMI <28 kg/m2 respectively according to the 
Chinese criteria(32). 
The difference in the quantitative traits including BMI, Fasting plasma glucose (FPG), 
Triglycerides (Trig), Hba1c and waist-to-hip ratio (w/h) was analyzed using a general linear model 
with BMI, FPG, Trig, Hba1c and w/h as the dependent variable, genotype as the independent 
variable and sex and age as covariates. The statistical analyses were performed using the SPSS 
(SPSS Inc., Chicago, IL, USA) program.  
Power calculations were performed on the G*Power program(33). All p values reported were 
two-tailed. Statistical significance was defined at p<0.05. 
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We certify that all applicable institutional and governmental regulations concerning the ethical use 
of human volunteers were followed during this research. A standard written informed consent, 
reviewed and approved by the ethics committee of the Shanghai Institute for Biological Sciences, 
Chinese Academy of Sciences, was obtained from all participating subjects who were given a full 
explanation of the study. 
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 Results 
Genotypic distributions of the two SNPs in cases and controls were in Hardy-Weinberg 
equilibrium (p>0.05). In power calculations using the G*Power 3 program, we found that the 
sample size had >97% power for rs1044498 and >99% for rs7754561 for detecting a relatively 
weak gene effect (OR=1.2) with α≤0.05.  
However, we found no significant difference in either allele or genotype frequencies between the 
total 1912 type 2 diabetes patient group and 2041 normal controls at either rs1044498 or 
rs7754561 under additive, dominant and recessive models either before or after adjusting for sex 
and age (Table 2).  
The estimation of linkage disequilibrium showed that rs1044498 and rs7754561 were not in a 
strong LD relationship with the standardized D’=0.782 and r2=0.049. We further analyzed the 
frequencies of the haplotypes of the 2 SNPs above the common lowest frequency threshold (at 
least 3% frequency in both case and control groups) and found a marginal association of haplotype 
C-G (p=0.05) which was reported in the previous study (Table 3). 
Given the important role played by the ENPP1 gene in insulin resistance and the association 
widely reported with obesity and metabolic syndromes, we carried out the same logistic regression 
model analysis for obesity and non-obesity as for type 2 diabetes subjects and normal controls 
(Table 4), and specifically examined the relationship between 2 SNPs and BMI, Fasting plasma 
glucose (FPG), Triglycerides (Trig), Hba1c, waist-to-hip ratio (w/h) in the control group using 
general linear model analysis (Table 5). No significant associations between polymorphisms of 
ENPP1 and obesity or the quantitative traits were observed either before or after adjusting for sex 
and age. 
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 Discussion 
Diabetes mellitus has reached epidemic proportions and affects more than 180 million individuals 
worldwide. Global estimates for the year 2010 predict a further growth of almost 50%, with the 
greatest increases in the developing countries of Africa, Asia, and South America(34). The 
problem is becoming serious especially in China, a country with a 1.3 billion population, with 
predictions that the number of patients who suffer type 2 diabetes is going to be highly significant 
in a future aging society. According to the WHO criteria, Diabetes mellitus is a metabolic disorder 
characterized by chronic hyperglycemia with disturbances of carbohydrate, fat and protein 
metabolism. This clinical phenomenon is likely to be partially attributable to impaired insulin 
secretion and insulin resistance in which some key genes play important roles. Research based on 
family, twin and adoption studies has established the genetic contribution to susceptibility to type 
2 diabetes. Over the past decade, genetic and gnome-wide association studies on TCF7L2, 
SLC30A8, HHEX, FTO, PPARG, KCNJ11, as well as ENPP1 have suggested possible relationship 
between allele and genotype frequencies and the pathogenesis of type 2 diabetes. 
The ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) gene, also known as plasma 
cell membrane glycoprotein 1 (PC-1), encodes for a type II transmembrane glycoprotein, which 
inhibits the insulin receptor and subsequent insulin signaling. When over-expressed in peripheral 
insulin target tissues, it is involved in human insulin resistance. The molecular mechanism 
responsible for the phenomenon was first reported to be associated with a nonsynonymous SNP 
K121Q(15) which produced the Q allele “gain-of-function” effect several times more effective 
than the K allele in reducing insulin stimulation of IR autophosphorylation, insulin receptor 
substrate-1 phosphorylation, phosphatidylinositol 3-kinase activity, glycogen synthesis, and cell 
proliferation(16). Further, genetic association analyses have supported these findings and have 
suggested that polymorphisms of ENPP1 are associated with the risk of type 2 diabetes, obesity 
and a series of metabolic syndromes.  
However, we failed to replicate positive association between rs1044498, rs7754561 and type 2 
diabetes or obesity in the Chinese Han population, except a marginal association between the two 
risk allele haplotype C-G and type 2 diabetes (p=0.05) which was reported in the previous 
study(22). In comparable studies the positive associations have often been reported in white(17, 20) 
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 and African(18) populations, whereas , negative results were found recently in Chinese(23) and 
Japanese(24) populations. Heterogeneity is still a factor, especially for a complicated metabolic 
disease. Moreover, unlike a single gene disease, type 2 diabetes and obesity are more attributable 
to multi-factorial pathogenesis caused by alterations in many gene products. Our study suggests 
that polymorphisms of ENPP1 might not play a major role in susceptibility to type 2 diabetes or 
obesity, but we cannot completely rule out the possible potential effects of ENPP1 allowing for the 
association evidence suggested by haplotype analysis and masking influence of different genetic 
backgrounds and environmental conditions. On the other hand, association studies are mainly 
concerned with the minor effect of genes or genotypes, so samples have to be large enough and 
have sufficient statistical power to deliver satisfactory results. Previous studies with positive 
results have been based on several relatively small samples, so further studies should have larger 
and more ethnically diverse samples. Our investigation on ENPP1 provides with the largest 
sample to date relating to type 2 diabetes and obesity in the Chinese population. 
The sample size of the IFG/IGT subject group was so small that we did not perform a case-control 
analysis between the IFG/IGT subject group and the control group, although it has been reported 
that both IFG and IGT are strong risk factors for the development of type 2 diabetes(35). 
In addition, we examined the relationship between the two SNPs and BMI, FPG, Trig, Hba1c and 
w/h in the control group using general linear model analysis, given that the physiological 
conditions of the patient group might be altered by medicines and treatments. None showed 
significant association with any of these metabolic quantitative traits. 
In conclusion, our case-control investigation in the Chinese Han population did not support 
positive association between two SNPs of ENPP1, rs1044498 and rs7754561, and type 2 diabetes 
or obesity. We hope the study may act as a reference point for further replication studies on the 
effects of ENPP1 on type 2 diabetes and obesity, and for the comprehensive meta-analyses which 
are required for validation.
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Table 1. Clinical characteristics of the subject samples 
 Type 2 diabetes IFG/IGT Control 
Age (years) 63.8±9 64±9 58.1±9 
BMI (kg/m2) 25.3±3.4 24.9±3.2 24.5±3.2 
Waist-to-hip ratio 0.90±0.06 0.88±0.06 0.86±0.06 
Fasting blood glucose(mmol/l) 8.1±2.9 5.6±0.68 4.8±0.64 
Triglycerides (mmol/l) 1.9±1.6 1.9±1.2 1.6±1.1 
Cholesterol (mmol/l) 4.5±0.9 4.5±0.8 4.5±0.9 
HDL (mmol/l) 1.2±0.3 1.1±0.3 1.3±0.3 
LDL (mmol/l) 2.8±0.8 2.8±0.7 2.8±0.7 
Systolic blood pressure(mmHg) 140.1±20.4 141.3±18.9 132±19.3 
Diastolic blood pressure(mmHg) 82.0±10.2 82.1±10.6 81.1±10.1 
HbA1C (%) 7.5±1.6 6.2±0.5 5.8±0.6 
Data are means ± SD 
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Table 2. Allele and genotype distributions of the SNPs in cases and controls 
 Risk-allele frequencies Unadjusted Genotype distribution Adjusted by sex, age and BMI 
SNPs Risk 
allele 
Control 
n (freq) 
IFG/IGT 
n (freq) 
T2D 
n (freq) 
OR (95% CI) 
 
Genotype Control 
n (freq) 
IFG/IGT 
n (freq) 
T2D 
n(freq) 
Additive 
model 
OR (95% CI) 
Dominant 
model 
OR (95% CI) 
Recessive 
model 
OR (95% CI) 
rs1044498 C 423(0.105) 50(0.108) 439(0.117) 0.89(0.77-1.02) CC 19(0.009) 4(0.017) 23(0.012) 1.15(0.97-1.34) 1.15(0.98-1.36) 1.33(0.70-2.54) 
     Pfreq =0.097 CA 385(0.191) 42(0.181) 393(0.209) Padd =0.076 Pdom =0.090 Prec =0.387 
      AA 1610(0.799) 186(0.802) 1463(0.779)    
rs7754561 G 2264(0.601) 224(0.526) 2063(0.596) 1.03(0.93-1.13) GG 678(0.360) 62(0.291) 631(0.364) 0.94(0.86-1.04) 0.85(0.71-1.03) 0.98(0.84-1.13) 
     Pfreq =0.607 GA 908(0.482) 100(0.469) 801(0.462) Padd =0.261 Pdom =0.094 Prec =0.734 
      AA 296(0.157) 51(0.239) 300(0.173)    
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Table 3. Estimated haplotype analysis in the case-control samples 
Haplotype 
Type 2 diabetes 
n(freq) 
Control n(freq) Fisher's p Odds Ratio (95%CI) 
A-A 1353.25(0.395) 1434.82(0.386) 0.485481 1.035 (0.940-1.138) 
A-G 1680.75(0.491) 1900.18(0.511) 0.063866 0.916 (0.834-1.005) 
C-G 362.25(0.106) 340.82(0.092) 0.050313 1.168 (1.000-1.365) 
Haplotype analysis excluded those with less than 3% estimated haplotype probability. The 
individual haplotype frequency differences between cases and controls were calculated using the 
SHEsis software platform. For each haplotype, alleles are arranged in order of rs1044498 - 
rs7754561. 
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Table 4. Allele and genotype distributions of the SNPs in the obese and non-obese subjects 
Risk-allele 
frequencies 
Unadjusted Genotype distribution Adjusted by sex and age 
SNPs 
 
 
Risk 
allele 
Obesity 
n (freq) 
Non-obesity 
n (freq) 
OR (95% CI) 
 
Genotype 
Obesity 
n (freq) 
Non-obesity 
n(freq) 
Additive 
model 
OR (95% CI) 
Dominant 
model 
OR (95% CI) 
Recessive 
model 
OR (95% CI) 
rs1044498 C 154(0.115) 697(0.1107) 0.96(0.85-1.09) CC 5(0.007) 37(0.012) 1.05(0.87-1.27) 1.09(0.89-1.33) 0.63(0.25-1.62) 
    Pfreq =0.550 CA 144(0.216) 623(0.196) Padd =0.597 Pdom =0.411 Prec =0.337 
     AA 519(0.777) 2518(0.792)    
rs7754561 G 749(0.607) 3526(0.597) 0.95(0.79-1.14) GG 678(0.360) 1065(0.361) 1.03(0.91-1.16) 1.02(0.83-1.24) 1.03(0.86-1.23) 
    Pfreq =0.552 GA 908(0.482) 1396(0.473) Padd =0.678 Pdom =0.878 Prec =0.789 
     AA 296(0.157) 492(0.167)    
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Table 5. Associations between the SNPs and quantitative traits of BMI, Fasting plasma glucose 
(FPG), Triglycerides (Trig), Hba1c and waist-to-hip ratio (w/h) 
SNPs 
Genotype 
(1/2) Trait 11 12 22 P 
rs1044498 A/C BMI (kg/m2) 24.3(22.3-26.5) 24.5(22.6-26.7) 24.8(22.9-26.6) 0.454 
  FPG (mmol/l) 4.90(4.51-5.26) 4.86(4.50-5.23) 4.74(4.44-5.00) 0.062 
  Trig 1.34(0.95-1.91) 1.32(0.93-1.96) 1.35(1.03-1.92) 0.846 
  Hba1c 5.81(5.47-6.10) 5.77(5.40-6.12) 5.89(5.41-6.13) 0.279 
  w/h 0.86(0.82-0.90) 0.86(0.82-0.91) 0.86(0.82-0.90) 0.186 
rs7754561 A/G BMI (kg/m2) 24.1(22.0-26.2) 24.3(22.3-26.5) 24.5(22.3-26.7) 0.054 
  FPG (mmol/l) 4.88(4.49-5.26) 4.89(4.539-5.27) 4.90(4.46-5.26) 0.123 
  Trig 1.34(0.94-1.88) 1.33(0.93-1.90) 1.36(0.94-1.96) 0.955 
  Hba1c 5.82(5.44-6.13) 5.82(5.47-6.13) 5.81(5.47-6.09) 0.938 
  w/h 0.86(0.82-0.89) 0.86(0.82-0.90) 0.86(0.82-0.90) 0.342 
Data are median (1st–3rd quartile). P values were derived using the additive model adjusted for 
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